Department of Cardiology and Vascular Medicine, Faculty of Medicine, University of Padjadjaran, Bandung, West Java, Indonesia.
Division of Cardiology, Department of Internal Medicine, Korea University Medical Center, Seoul, South Korea.
Am J Case Rep. 2024 Oct 25;25:e945005. doi: 10.12659/AJCR.945005.
BACKGROUND Brugada syndrome (BrS) is a cardiac arrhythmia disorder characterized by ventricular arrhythmias, which can lead to sudden cardiac death (SCD). BrS is also associated with atrial arrhythmias, particularly atrial fibrillation (AF). There is ongoing debate regarding whether treated AF can still precipitate ventricular arrhythmias in patients with BrS. This case series aims to elucidate the prognostic significance of treated AF in BrS patients who experienced SCD. CASE REPORT We report on 2 patients diagnosed with Brugada syndrome (BrS) who presented with atrial fibrillation (AF). Both patients exhibited type I Brugada electrocardiographic patterns, and echocardiographic assessments revealed normal cardiac structure and function. Thyroid function tests and electrolyte levels were within normal ranges. An electrophysiology study (EPS) performed on the first patient demonstrated the induction and termination of AF, but no inducible ventricular arrhythmia was observed. Both patients declined the ablation procedure for AF treatment, opting instead for pharmacologic rhythm control with amiodarone. During follow-up visits every 3 months, neither patient reported palpitations or syncope, and electrocardiography consistently indicated sinus rhythm. Despite this, sudden cardiac death (SCD) occurred in the first patient during the first year of follow-up and in the second patient during the second year of follow-up. CONCLUSIONS Patients with BrS who have treated AF remain at a high risk of SCD. The presence of AF in BrS patients may indicate a specific variant of the SCN5A mutation, which can heighten the risk of ventricular arrhythmias and consequent SCD.
Brugada 综合征(BrS)是一种以室性心律失常为特征的心律失常性心脏病,可导致心源性猝死(SCD)。BrS 还与房性心律失常有关,特别是心房颤动(AF)。目前仍在争论治疗后的 AF 是否仍会引发 BrS 患者的室性心律失常。本病例系列旨在阐明在经历 SCD 的 BrS 患者中,治疗后的 AF 的预后意义。
我们报告了 2 例诊断为 Brugada 综合征(BrS)的患者,他们均表现为心房颤动(AF)。这 2 例患者均表现为 I 型 Brugada 心电图模式,超声心动图评估显示心脏结构和功能正常。甲状腺功能检查和电解质水平均在正常范围内。对第 1 例患者进行的电生理研究(EPS)显示 AF 的诱导和终止,但未观察到可诱导的室性心律失常。这 2 例患者均拒绝进行 AF 消融治疗,而选择胺碘酮进行药物节律控制。在每 3 个月一次的随访中,这 2 例患者均未报告心悸或晕厥,心电图持续显示窦性心律。尽管如此,第 1 例患者在随访的第 1 年内和第 2 例患者在随访的第 2 年内发生了心源性猝死(SCD)。
治疗后的 AF 仍使 BrS 患者处于高 SCD 风险中。BrS 患者出现 AF 可能表明存在 SCN5A 突变的特定变异,这可能会增加室性心律失常和随后 SCD 的风险。